Sanofi Ventures
Sanofi Ventures operates as the corporate venture capital arm of Sanofi.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Sanofi Ventures Information
Geographic Data
Address: 50 Binney Street
City: Cambridge
State: MA
Zip: 02142
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
6,601,935Website Global Rank
818Website Monthly Traffic
Twitter Followers
Description
Sanofi Ventures is the corporate venture capital arm of Sanofi. We have the ability to seed and to lead financings in early-stage companies with innovative ideas and transformative new products and technologies that are of strategic interest to Sanofi. Among these areas are rare diseases, oncology, immunology and inflammation, vaccines, potential cures in other core areas of Sanofi’s business footprint, and digital health and data science solutions.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2014 | Lysosomal Therapeutics | Seed Round | 4.8M |
| 10/2014 | Cogent Biosciences | Series A | 12.3M |
| 6/2021 | Glycomine | Series B | 0 |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 6/2017 | Omada Health | Series C | 50M |
| 1/2018 | Expansion Therapeutics | Series A | 55.3M |
| 4/2023 | Therini Bio | Series A | 0 |
| 3/2023 | QurAlis | Series B | 0 |
| 10/2021 | Click Therapeutics | Series B | 0 |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 2/2019 | Aetion | Series B | 0 |
| 9/2019 | Veralox Therapeutics | Seed Round | 0 |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
| 1/2021 | Abcuro | Series A | 42M |
| 11/2009 | Fate Therapeutics | Series B | 30M |
| 12/2015 | Navitor Pharmaceuticals | Series B | 33M |
| 9/2015 | Selecta Biosciences | Series E | 38M |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 1/2023 | NextPoint Therapeutics | Series B | 0 |
| 12/2009 | GlycoMimetics | Series C | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 4/2021 | Icosavax | Series B | 0 |
| 12/2017 | Curisium | Seed Round | 3.5M |
| 8/2020 | Science 37 | Venture Round | 0 |
| 4/2017 | Science 37 | Series C | 35M |
| 9/2020 | Lava Therapeutics | Series C | 83M |
| 12/2020 | Minervax | Series B | 57.6M |
| 12/2022 | Minervax | Series C | 0 |
| 8/2008 | Proteostasis Therapeutics | Series A | 45M |
| 6/2020 | NodThera | Series B | 55M |
| 8/2015 | Ovid Therapeutics | Series B | 75M |
| 3/2016 | ImmuneXcite | Series A | 8.6M |
| 9/2015 | Proteostasis Therapeutics | Series B | 37M |
| 2/2021 | Medisafe | Series C | 0 |
| 4/2022 | OMass Technologies | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 80M |
| 10/2019 | Icosavax | Series A | 0 |
| 7/2018 | Imbria Pharmaceuticals | Seed Round | - |
| 3/2010 | Bluebird Bio | Series B | 35M |
| 3/2022 | Nucleai | Series B | 0 |
| 4/2018 | Common Sensing | Series A | 0 |
| 11/2017 | Inozyme | Series A | 49M |
| 2/2023 | Avilar Therapeutics | Seed Round | 0 |
| 7/2020 | Kalobios Pharmaceuticals, Inc. | Seed Round | - |
| 6/2022 | ReCode Therapeutics | Series B | 0 |
| 4/2017 | Evidation Health | Venture Round | 10M |
| 5/2021 | Therini Bio | Seed Round | 0 |
| 11/2022 | Escient Pharmaceuticals | Series C | 120M |
| 4/2020 | i2o Therapeutics | Seed Round | 4M |
| 11/2018 | Kymera Therapeutics | Series B | 65M |
| 10/2022 | Matchpoint Therapeutics | Series A | 70M |
| 10/2016 | Science 37 | Series B | 31M |
| 4/2019 | Inozyme | Series A | 67.4M |
| 5/2020 | Q32 Bio | Series A | 46M |
| 10/2020 | Q32 Bio | Series B | 60M |
| 4/2006 | Sirtris Pharmaceuticals | Series C | 37M |
| 7/2013 | Edimer | Series B | 18M |
| 8/2022 | Empatica | Series B | 25.9M |
| 9/2013 | KAHR medical | Series A | 2.5M |
| 10/2018 | Click Therapeutics | Series A | 19M |
| 6/2019 | Omada Health | Series D | 73M |
| 8/2018 | Evidation Health | Series C | 30M |
| 10/2022 | Normunity | Series A | 65M |
| 10/2013 | Immune Design | Series C | 49M |
| 6/2015 | Cogent Biosciences | Series B | 65M |
| 5/2013 | Lumena Pharmaceuticals | Series A | 23M |
| 12/2007 | NGI | Series A | 11.8M |
| 2/2015 | Lysosomal Therapeutics | Series A | 20M |
| 2/2016 | Yumanity Therapeutics | Series A | 51M |
| 7/2017 | NeuroVia | Series A | 14M |
| 6/2022 | ReCode Therapeutics | Series B | 0 |
| 4/2022 | OMass Technologies | Series B | 0 |
| 3/2022 | Nucleai | Series B | 0 |
| 10/2021 | Click Therapeutics | Series B | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 9/2021 | Expansion Therapeutics | Series B | 0 |
| 9/2021 | ROME Therapeutics | Series B | 0 |
| 7/2021 | Muna Therapeutics | Series A | 0 |
| 6/2021 | Glycomine | Series B | 0 |
| 6/2021 | Veralox Therapeutics | Series A | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
